



0040-4020(94)E0152-J

Claisen Rearrangement of *N*-Silyl Ketene *N,O*-Acetals Generated from Allyl *N*-Phenylimidates

Peter Metz* and Cornelia Linz


Organisch-Chemisches Institut der Universität Münster, Corrensstraße 40, D-48149 Münster, Germany

Abstract: Deprotonation and subsequent *N*-silylation of allyl *N*-phenylimidates **1** lead to *N*-silyl ketene *N,O*-acetals **5** which undergo a Claisen rearrangement to yield γ,δ -unsaturated anilides **3** after hydrolytic work-up. The temperature for the rearrangement step is dependent on the nature of the substituent R^2 in **5**. Ketene acetals **5** with $R^2 = H$ rearrange readily at room temperature, while heating at 130 °C is required if $R^2 \neq H$. The degree of simple diastereoselection attainable for the conversion of **1** to **3** is strongly affected by the size of the substituent R^4 . With $R^4 > H$ excellent *anti/syn* selectivity is caused by efficient suppression of the rearrangement pathway via a boat transition state. This rationale is supported by NOE difference data obtained for several allyl *N*-phenylimidates and *N*-silyl ketene *N,O*-acetals.

INTRODUCTION


The thermal isomerization of allyl *N*-phenylimidates **1** via ketene *N,O*-acetals **2** constitutes a simple protocol for the synthesis of γ,δ -unsaturated anilides **3** (Scheme 1).^{1a} However, due to the non-stereoselective formation of the ketene acetal moiety within intermediates **2**, only a moderate control over the relative configuration of the two newly formed stereogenic centers α and β to the carbonyl group in **3** is achieved.

In the course of our studies on rearrangement reactions of allyl imidates,¹ we have developed an alternative procedure for the conversion of **1** to **3** by Claisen rearrangement² of *N*-silyl ketene *N,O*-acetals generated from **1** through deprotonation and subsequent *N*-silylation.^{1b,3} This method provides a highly diastereoselective access to amides **3** which can be hydrolyzed to the corresponding carboxylic acids without epimerization.⁴ Here, we give a full account of our investigations on the title reaction including NOE difference studies of educts and *N*-silyl ketene *N,O*-acetals.



Scheme 1. Claisen rearrangement via thermal isomerization of allyl *N*-phenylimidates **1**

In order to find suitable conditions for the deprotonation of allyl *N*-phenylimidates **1**, model substrate **1a** was treated with a broad range of bases⁵ followed by an excess of ethylide. Eventually, it turned out that the use of lithium diethylamide⁶ allowed for a complete conversion of **1a** and led to a good yield of alkylation product **4** (Scheme 2).⁷




Scheme 2. Deprotonation/alkylation of allyl *N*-phenylimidate **1a** (LDEA = lithium diethylamide)

RESULTS AND DISCUSSION

General Features of the Deprotonation/Silylation Sequence

Deprotonation of allyl *N*-phenylimidates **1** with lithium diethylamide and silylation of the resultant azaenolates with *tert*-butyldimethylchlorosilane afford *N*-silyl ketene *N,O*-acetals **5**.⁸ Without isolation, these intermediates were rearranged to *N*-silylated amides which smoothly hydrolyzed to anilides **3** on aqueous work-up in moderate to good overall yields (Scheme 3, Table 1). Starting from substrates **1** with $R^2 = \text{H}$, Claisen rearrangement of the corresponding ketene acetals **5** is complete after 24 h at room temperature, whereas no rearrangement is detectable for substrates with $R^2 \neq \text{H}$ under these conditions. The rearrangement step for the latter substrates (entries 3,5,7,8) is best performed by heating the intermediates **5** at 130 °C for 48 h after exchanging the solvent THF against decalin.

In contrast to the thermal isomerization of allyl imidates,^{1a} a sterically unfavorable formation of a β -quaternary center is easily accomplished (entry 8), and imidate **1g** (entry 9) derived from a secondary alcohol leads exclusively to (*E*)-configured **3g**, while simple heating of **1g** also produces 2.8 % of the (*Z*)-isomer.^{1a}




Scheme 3. Claisen rearrangement *via* deprotonation/silylation of allyl *N*-phenylimidates **1** (LDEA = lithium diethylamide; TBDMSCl = *tert*-butyldimethylchlorosilane)

Table 1. Claisen rearrangement of *N*-silyl ketene *N,O*-acetals **5** generated from allyl *N*-phenylimidates **1**.

entry	1	R ¹	R ²	R ³	R ⁴	R ⁵	T [°C]	3	Yield [%] ^a
1	a	Me	H	Me	H	H	20	a	67
2	(<i>E</i>)- b	Me	H	<i>n</i> -Pr	H	H	20	b	66
3	(<i>Z</i>)- b	Me	<i>n</i> -Pr	H	H	H	130	b	63
4	(<i>E</i>)- c	Me	H	Me	Me	H	20	c	59
5	(<i>Z</i>)- c	Me	Me	H	Me	H	130	c	70
6	d	Me	H	Me	SiMe ₃	H	20	d	64
7	e	Me	Me	H	SiEt ₃	H	130	e	38
8	f	Me	Me	Me	H	H	130	f	56
9	g	Me	H	H	H	Me	20	g	55 ^b
10	h	Ph	H	Me	H	H	20	h	47
11	i	OMe	H	Me	H	H	20	i	54

^a Yield of anilides **3** after chromatographic purification. ^b Only (*E*)-**3g** by capillary GC analysis of the crude product.



Scheme 4. Preparation of allyl alcohols **7a** and **7b**. a: (i) DIBAH, ether, 35 °C, (ii) MeLi, 20 °C, (iii) (CH₂O)_x, ether, 20 °C; b: *t*-BuCOCl, DMAP, Et₃N, CH₂Cl₂, 20 °C; c: Et₃SiH, H₂PtCl₆·H₂O, 100 - 120 °C; d: LiAlH₄, ether, reflux (DIBAH = di-*iso*-butylaluminum hydride; DMAP = 4-*N,N*-(dimethylamino)pyridine)

Scheme 4 illustrates the preparation of trialkylsilyl substituted alcohols **7a** and **7b** required for the synthesis of allyl imidates **1d** and **1e**, respectively. Regio- and stereoselective hydroalumination⁹ of alkyne **6** followed by hydroxymethylation¹⁰ directly yielded **7a** as a single isomer, thus providing an efficient alternative to the published multi-step route¹¹ to this compound. Alcohol **7b** was prepared according to the procedure of Stork and co-workers from alkyne **8** via directed hydrosilylation of pivalate **9** and subsequent reduction.¹² In our hands, a mixture of **10** and **11** (4.0 : 1) was obtained in the key step, but pure **7b** was easily isolated by flash chromatography after reductive ester cleavage.

Allyl *N*-phenylimidates **1** were synthesized under standard conditions^{1a} from amides **13** and the lithium salts of the requisite allyl alcohols (Table 2).

Table 2. Preparation of allyl *N*-phenylimidates **1**.^a

13	R ¹	7	R ²	R ³	R ⁴	1	Yield [%] ^b
a	Me	(<i>Z</i>)- c ^c	Me	H	Me	(<i>Z</i>)- c	62
a	Me	a	H	Me	SiMe ₃	d	62
a	Me	b	Me	H	SiEt ₃	e	64 ^d
b	OMe ^e	d ^f	H	Me	H	i	44

^a For the preparation of the other imidates **1** used in this study, see ref 1a. ^b Yield of distilled imidates **1**. ^c Ref 13. ^d Yield after chromatographic purification. ^e Ref 14. ^f Ref 15.

Simple Diastereoselectivity

A central issue of our study was the determination of the simple diastereoselectivity attainable by this new variant of the Claisen rearrangement. The diastereomeric ratios listed in Table 3 exceed the corresponding values for the thermal isomerization of allyl imidates **1** by far and, moreover, they are complementary to the latter.^{1a} Thus, (*E*)-configured¹⁶ substrates **1** lead preferably to *anti*-**3**, whereas (*Z*)-configured¹⁶ imidates **1** yield mainly *syn*-**3**.¹⁷

In the series of (*E*)-configured substrates **1**, a pronounced increase in diastereoselection is noted with increasing size of substituent R⁴ along the line **1a** (R⁴ = H), (*E*)-**1c** (R⁴ = Me), and **1d** (R⁴ = SiMe₃). Compared to **1a**, *anti* selectivity is decreased for R¹ = Ph (**1h**) though still being in a preparatively useful range, while R¹ = OMe (**1i**) causes a nearly stereorandom reaction.

For the Ireland variant of the Claisen rearrangement starting from allyl esters, a change of the solvent during the enolization step can switch the relative configuration of the major rearranged product.¹⁸ To determine whether a similar solvent effect is operative for allyl *N*-phenylimidates **1** as well, **1a** was deprotonated in a mixture of THF and hexamethylphosphoric triamide, too. However, this modification did not alter the *anti*/*syn* ratio of products **3a** recorded in Table 3.

Table 3. Simple diastereoselectivity of the Claisen rearrangement of *N*-silyl ketene *N,O*-acetals generated from allyl *N*-phenylimidates **1**.^a


1	R ¹	R ³	R ⁴	<i>anti</i> -3	:	<i>syn</i> -3	3
a	Me	Me	H	90.7	:	9.3	a
<i>(E)</i> - b	Me	<i>n</i> -Pr	H	90.9	:	9.1	b
<i>(E)</i> - c	Me	Me	Me	98.1	:	1.9	c
d	Me	Me	SiMe ₃	99.2	:	0.8	d
h	Ph	Me	H	83.2	:	16.8	h
i	OMe	Me	H	46.6	:	53.4	i

1	R ¹	R ²	R ⁴	<i>anti</i> -3	:	<i>syn</i> -3	3
<i>(Z)</i> - b	Me	<i>n</i> -Pr	H	11.5	:	88.5 ^b	b
<i>(Z)</i> - c	Me	Me	Me	3.9	:	96.1 ^b	c
e	Me	Me	SiEt ₃	1.6	:	98.4	e


^a Determined by capillary GC analysis of the crude anilides **3**. ^b Corrected for 100 % (*Z*)-educt.

On the other hand, good to excellent *syn* selectivity is observed for (*Z*)-configured substrates **1**. Whereas the extreme reactivity difference between (*E*)- and (*Z*)-configured imidates **1** allows for a chemoselective conversion of the (*E*) isomer from an isomeric mixture at room temperature, high geometrical purity of the (*Z*) substrates **1** is essential to achieve a highly *syn* selective rearrangement. As is inferred from the last three entries in Table 3, the substituent R⁴ again has a marked effect on the degree of diastereoselection.

Since anilides *anti*-**3d** and *syn*-**3e** are readily protodesilylated¹⁹ to *anti*-**3a** and *syn*-**3a** without epimerization α to the carbonyl group, respectively, the trialkylsilyl groups in **1d** and **1e** may be regarded as temporary substituents for stereocontrol,²⁰ eventually providing an access to amides **3** with R⁴ = H of very high stereoisomeric purity (Scheme 5). Moreover, in view of the broad synthetic potential of vinylsilanes,^{19a} introduction of various groups at C-4 is easily envisioned from **3d** and **3e**.

Scheme 5. Desilylation of anilides *anti-3d* and *syn-3e*

With the exception of **3i**, the relative configuration of all major product stereoisomers is compatible with a (*Z*)-configuration of the vinylic double bond in the intermediate *N*-silyl ketene *N,O*-acetals **5** and a chair transition state geometry for the rearrangement step.² It appeared highly improbable to us, that the substituent **R**⁴ exerts a significant influence on the stereoselectivity of azaenolate formation, i.e. the lower *anti/syn* ratio obtained from **1a** compared to (*E*)-**1c** and **1d** should not be due to different proportions of the corresponding intermediates **5** containing an (*E*)-configured ketene *N,O*-acetal moiety. As a more plausible explanation, all *N*-silyl ketene *N,O*-acetals **5** for **R**¹ ≠ OMe are > 99 % (*Z*)-configured and stereochemical differentiation ensues from the participation of both chair and boat transition state geometries.

Scheme 6. Stereoelectronically controlled formation of *N*-silyl ketene *N,O*-acetals (LDEA = lithium diethylamide; TBDMSCl = *tert*-butyldimethylchlorosilane)

Indeed, if allyl *N*-phenylimidates **1** existed solely as (*E*[C=N]) isomers, as is usually the case for *N*-alkyl imidates,^{6,21} a stereoelectronically controlled deprotonation of the conformer of (*E*[C=N])-**1** with minimized A^{1,3}-strain would yield (*Z*)-**5** (Scheme 6).^{6,22} For R¹ = OMe, however, generation of an (*E*) azaenolate would enable chelate formation. The striking drop in stereoselectivity observed for Claisen rearrangement starting from **1i** is attributable to a compensation of these two opposing factors.

Since all imidates **1** as well as *N*-silyl ketene *N,O*-acetals **5** containing a (*Z*)-configured allyl moiety are stable species at room temperature, it was possible to verify the assumptions regarding the geometry of the C,N double bond in **1** and the configuration of the vinylic double bond in **5** by NOE difference studies.^{21c,23}

According to capillary GC, ¹H NMR, and ¹³C NMR data, imidates **1** are stereochemically homogeneous about the C,N double bond. Figure 1 illustrates the results of NOE difference spectral analyses for (*Z*)-**1b** and **1a**. While irradiation of the methylene protons α to C=N and of the adjacent methyl protons resulted in significant enhancements for the *ortho* phenyl protons, respectively, no corresponding effect was noted for irradiation of the methylene protons adjacent to oxygen. These data strongly support an (*E*[C=N]) configuration.




Figure 1. Selected NOE difference data for allyl *N*-phenylimidates (*Z*)-**1b** and **1a**

N-silyl ketene *N,O*-acetals **5** derived from (*E*)-configured allyl alcohols already rearrange at room temperature. Hence, allyl *N*-phenylimidate (*Z*)-**1b** and ethyl *N*-phenylpropanimidate²⁴ were deprotonated, and after subsequent silylation, *N*-silyl ketene *N,O*-acetals (*1Z,2'Z*)-**5b** and (*Z*)-**14** were isolated, respectively. These compounds were homogeneous by ¹H and ¹³C NMR spectroscopy, too. Figure 2 depicts characteristic NOE difference data for (*1Z,2'Z*)-**5b** and (*Z*)-**14**.




Figure 2. Selected NOE difference data for *N*-silyl ketene *N,O*-acetals (*1Z,2'Z*)-**5b** and (*Z*)-**14**

While irradiation of a four proton multiplet of the phenyl group produced enhancements of 1.5 % (3.2 %) for the vinylic hydrogen, enhancements of only 0.2 % were observed for the protons of the vinylic methyl group in these experiments. In addition to these data which clearly indicate a (*Z*)-configured ketene acetal moiety, enhancements of 1.4 % (1.9 %) were recorded for the methylene protons adjacent to oxygen. Thus, rotation around the C-1,N bond of (1*Z*,2'*Z*)-**5b** and (*Z*)-**14** is possible.

Since these NOE studies confirm that only *N*-silyl ketene *N,O*-acetals **5** with a (*Z*)-configured vinylic double bond ($R^1 \neq \text{OMe}$) are involved in the rearrangement step, a competition between reaction pathways via chair transition state **TS(1)** and boat transition state **TS(2)** is responsible for the varying diastereomeric ratios of anilides **3** listed in Table 3 (Figure 3).




Figure 3. Competing pathways for the Claisen rearrangement of *N*-silyl ketene *N,O*-acetals (*1Z*)-**5**

To what extent a reaction course *via* TS(2) intervenes, is significantly influenced by the size of substituent R⁴.²⁵ For R⁴ = H (1a, (*E*)-1b), about 9 % of the intermediates 5 react *via* TS(2),²⁶ whereas for R⁴ = Me ((*E*)-1c) and even more pronounced for R⁴ = SiMe₃ (1d), the increased eclipsic interaction between R⁴ and the bulky amino substituent causes an efficient suppression of the reaction pathway *via* boat transition state TS(2).²⁷ While Figure 3 is depicted for (*E*)-configured allyl moieties, the rationale given above also applies to the reaction of the (*Z*)-configured isomers as is easily seen after exchanging R³ against H and the hydrogen atom geminal to R³ against R².

EXPERIMENTAL

General Remarks

All reactions requiring exclusion of moisture were run under argon using flame-dried glassware. Solvents were dried by distillation from benzophenone ketyl (THF, ether) or else from CaH₂. Flash chromatography was performed on Merck silica gel 60 (40 - 63 μm). Capillary GC analyses were performed with a Shimadzu GC-14APFsc, a Shimadzu C-R6A integrator, an OV 225 CB column, 25 m length, 0.25 mm i. d., 0.25 μm film (column 1), a SE 54 CB column, 25 m length, 0.25 mm i. d., 0.25 μm film (column 2), a FFAP CB column, 50 m length, 0.32 mm i. d., 0.25 μm film (column 3), and a FFAP CB column, 50 m length, 0.20 mm i. d., 0.3 μm film (column 4). HPLC separations were performed with a Knauer 64 pump, a Knauer 51.78 differential refractometer, a Knauer 42.00 recorder, a Rheodyne 7125 injector, and a Knauer Polygosil 60 (5 μm) column, 250 mm length, 32 mm i. d.. Boiling points for bulb-to-bulb distillations refer to bath temperatures. Melting points were determined on a Kofler microscope desk. ¹H NMR spectra (300 MHz, CDCl₃), NOE difference spectra (300 MHz, CDCl₃) and ¹³C NMR spectra (75.47 MHz, CDCl₃) were obtained on a Bruker WM 300 - m_c = multiplet centered at, br. = broad. ¹³C multiplicities were determined using INEPT or DEPT pulse sequences. IR spectra (CHCl₃) were obtained on a Shimadzu IR-408 and a Nicolet 5DXC FT-IR. Mass spectra (70 eV) were recorded with a Varian MAT CH-7A + data system Finnigan MAT 200 (GC/MS), a Finnigan MAT 8230 + data system Finnigan SS 300 (GC/MS), and a Varian MAT CH-7 + data system Varian SS 200. Microanalyses were performed by the analytical laboratory of the Organisch-Chemisches Institut, Universität Münster, and by Mikroanalytisches Laboratorium M. Beller, Göttingen.

Allyl Alcohols 7

Except for 7a, the required allyl alcohols were either purchased from Aldrich (capillary GC analysis using column 1, 50 °C isothermal, indicated a (*Z*)/(*E*) ratio of 97.2:2.8 for the alcohol converted to allyl *N*-phenylimidate (*Z*)-1b) or prepared according to published procedures (cf. ref 1a; (*Z*)-7c: ref 13, (*Z*)/(*E*) = 98:2 by ¹H NMR integration).

Preparation of 7a. 1-(Trimethylsilyl)propyne (6; 6.5 ml, 43.9 mmol) is added dropwise at room temperature (water bath) to a solution of di-*iso*-butylaluminum hydride (8.73 ml, 49 mmol) in ether (22 ml). The mixture is heated to 35 °C for 1 h, cooled to 0 °C, and treated with methyllithium (30.3 ml, 1.6 M in ether). After stirring for 10 min at room temperature, the resultant solution is added dropwise to a suspension of paraformaldehyde (10.5 g, 350 mmol) in ether (22 ml) cooled to 0 °C. The mixture is stirred for 24 h at room temperature and poured into ice-cooled 1 N H₂SO₄ (100 ml). After extraction with ether (4 x 70 ml), the organic layers are washed with brine (70 ml), dried over MgSO₄, and concentrated *in vacuo* (rotary evaporator, 40 °C bath temperature). Bulb-to-bulb distillation (79 °C/15 Torr) yields 7a (4.92 g, 78 %) as a colorless liquid. No geometric isomer of 7a was detected with any of the GC columns applied in this study.

(*Z*)-2-Trimethylsilyl-2-buten-1-ol (7a).¹¹ ¹H NMR δ 0.19 [s, 9 H, Si(CH₃)₃], 1.80 (br. d, 3 H, *J* = 6.9 Hz, CH-CH₃), 4.12 (br. s, 2 H, OCH₂), 6.30 (tq, 1 H, *J*_t = 1.2 Hz, *J*_q = 6.9 Hz, CH-CH₃); ¹³C NMR δ -0.3 (q), 17.3 (q), 68.7 (t), 138.3 (d), 139.8 (s); IR 3609 (O-H) cm⁻¹; MS (GC/MS) *m/e* (relative intensity): 129 (M⁺ - CH₃,

11), 111 ($M^+ - CH_3 - H_2O$, 1), 75 [$(CH_3)_2Si=OH^+$, 100], 73 [$(CH_3)_3Si^+$, 44]. HRMS Calcd for $C_6H_{13}OSi$ ($M^+ - CH_3$): 129.0736. Found: 129.0737.

Preparation of 9. To a solution of 2,2-dimethylpropionylchloride (4.07 ml, 33.1 mmol) in CH_2Cl_2 (20 ml) cooled to 0 °C is added 4-(*N,N*-dimethylamino)pyridine (0.4 g, 3.27 mmol) followed by a solution of 2-butyne-1-ol (**8**; 2.1 g, 30 mmol) and triethylamine (8.36 ml, 60 mmol) in CH_2Cl_2 (10 ml). After stirring the resultant mixture for 1 h at 0 °C and 24 h at room temperature, it is diluted with CH_2Cl_2 (70 ml), washed successively with 2 N HCl (30 ml), sat. aqueous $NaHCO_3$ (30 ml), and brine (30 ml), and dried over $MgSO_4$. The solvent is removed *in vacuo* (rotary evaporator, 20 °C bath temperature), and the crude product is purified by fractional distillation (94 °C/15 Torr) to give **9** (3.74 g, 81 %) as a colorless liquid.

2-Butyn-1-yl 2,2-Dimethylpropionate (9).¹² 1H NMR δ 1.19 [s, 9 H, $C(CH_3)_3$], 1.83 (t, 3 H, $J = 2.3$ Hz, $CH_2-CC-CH_3$), 4.59 (q, 2 H, $J = 2.3$ Hz, OCH_2); MS (GC/MS) *m/e* (relative intensity): 154 (M^+ , 3), 85 [$(CH_3)_3C-CO^+$, 19], 57 [$(CH_3)_3C^+$, 100].

Preparation of 10. A mixture of alkyne **9** (3.1 g, 20.1 mmol), triethylsilane (3.21 ml, 20.1 mmol), and a 10 % aqueous solution of $H_2PtCl_6 \cdot H_2O$ (0.5 g, 0.12 mmol) is stirred under argon for 2 h at 120 °C and 3 h at 100 °C. After cooling to room temperature, the mixture is diluted with ether (120 ml), washed with sat. aqueous $NaHCO_3$ (30 ml) and water (30 ml), filtered, and dried over $MgSO_4$. The solvent is removed *in vacuo*, and the crude product is fractionally distilled (81 - 84 °C/0.53 Torr) to yield a mixture of **10** and **11** (3.92 g, 72 %) as a colorless liquid. Capillary GC analysis using column 1, 50 - 200 °C, 5 °C/min, then 200 °C isothermal, indicated a ratio **10**:**11** = 4.0:1 for the distilled as well as for the crude product.

(E)-2-Triethylsilyl-2-buten-1-yl 2,2-Dimethylpropionate (10).¹² 1H NMR δ 0.61 [q, 6 H, $J = 7.8$ Hz, $Si(CH_2-CH_3)_3$], 0.91 [t, 9 H, $J = 7.8$ Hz, $Si(CH_2CH_3)_3$], 1.20 [s, 9 H, $C(CH_3)_3$], 1.78 (d, 3 H, $J = 6.8$ Hz, $C=CH-CH_3$), 4.66 (s, 2 H, OCH_2) 6.07 (br. q, 1 H, $J = 6.8$ Hz, $C=CH-CH_3$); MS (GC/MS) *m/e* (relative intensity): 241 ($M^+ - C_2H_5$, 17), 187 [$(CH_3)_3C-CO-O=Si(C_2H_5)_2^+$, 100], 172 [$M^+ - CH_2=C=CH-CH_3 - CH_3$, 12], 57 [$(CH_3)_3C^+$, 32].

(E)-3-Triethylsilyl-2-buten-1-yl 2,2-Dimethylpropionate (11). 1H NMR (separable signals) δ 1.72 (s, 3 H, $CH=C-CH_3$), 5.76 (br. t, 1 H, $J = 6$ Hz, $C=CH$); MS (GC/MS) *m/e* (relative intensity): 241 ($M^+ - C_2H_5$, 10), 187 [$(CH_3)_3C-CO-O=Si(C_2H_5)_2^+$, 100], 172 ($M^+ - CH_2=C=CH-CH_3 - CH_3$, 6), 57 [$(CH_3)_3C^+$, 22].

Preparation of 7b. A solution of the 4.0:1 mixture of **10** and **11** (5.93 g, 21.9 mmol **10** + **11**; 17.5 mmol **10**) in ether (22 ml) is added dropwise to a suspension of $LiAlH_4$ (831 mg, 21.9 mmol) in ether (90 ml) cooled to 0 °C. After heating at reflux for 2 h, the mixture is cooled to 0 °C, and water (2.3 ml) is added slowly. The ethereal layer is decanted, the residue is extracted inside the reaction flask with ether (3 x 100 ml), and the combined organic layers are dried over $MgSO_4$. Removal of the solvent *in vacuo* and subsequent flash chromatography (ethyl acetate/petroleum ether 1:9, including 1 vol % triethylamine) affords **7b** (2.87 g, 70 % on mixture of **10** + **11**, 88 % on **10**) as a colorless liquid and a small amount of **12**. No geometric isomer of **7b** was detected with any of the GC columns applied in this study.

(E)-2-Triethylsilyl-2-buten-1-ol (7b).¹² 1H NMR δ 0.63 [q, 6 H, $J = 7.8$ Hz, $Si(CH_2-CH_3)_3$], 0.93 [t, 9 H, $J = 7.8$ Hz, $Si(CH_2CH_3)_3$], 1.79 (d, 3 H, $J = 6.8$ Hz, $C=CH-CH_3$), 4.26 (s, 2 H, OCH_2), 5.98 (br. q, 1 H, $J = 6.8$ Hz, $C=CH-CH_3$); ^{13}C NMR δ 3.2 (t), 7.4 (q), 14.6 (q), 60.3 (t), 138.4 (s), 139.1 (d); IR 3616 (O-H), 1614 ($C=C$) cm^{-1} ; MS (GC/MS) *m/e* (relative intensity): 157 ($M^+ - C_2H_5$, 4), 129 ($M^+ - C_2H_5 - CO$, 18), 103 [$(C_2H_5)_2Si=OH^+$, 100], 75 (80).

(*E*)-3-Triethylsilyl-2-buten-1-ol (**12**). $^1\text{H NMR } \delta$ 0.60 [br. q, 6 H, $J = 7.9$ Hz, $\text{Si}(\text{CH}_2\text{-CH}_3)_3$], 0.92 [t, 9 H, $J = 7.9$ Hz, $\text{Si}(\text{CH}_2\text{CH}_3)_3$], 1.69 (br. s, 3 H, $\text{CH}=\text{C-CH}_3$), 4.28 (br. d, 2 H, $J = 5.9$ Hz, OCH_2), 5.86 (qt, 1 H, $J_q = 1.7$ Hz, $J_t = 5.9$ Hz, $\text{C}=\text{CH}$); MS (GC/MS) m/e (relative intensity): 186 (M^+ , 2), 157 ($\text{M}^+ - \text{C}_2\text{H}_5$, 82), 129 ($\text{M}^+ - \text{C}_2\text{H}_5 - \text{CO}$, 41), 103 [$(\text{C}_2\text{H}_5)_2\text{Si}=\text{OH}^+$, 80], 75 (100).

Imidates **1**

The general procedure in ref 1a is followed (for yields, see Table 2). **1e** is purified by chromatography (14 g basic alumina, activity III, for preparation on a 2.22 mmol scale; elution with ethyl acetate/petroleum ether 1:9, including 1 vol % triethylamine).

(*Z*)/(*E*) ratios for (*Z*)-**1b** (97.5:2.5) and (*Z*)-**1c** (98.5:1.5) were determined by capillary GC analysis using column 2, 50 - 200 °C, 5 °C/min, then 200 °C isothermal; for **1e** no geometric isomer was detected with any of the GC columns applied in this study.

(*E*)-2-Buten-1-yl *N*-Phenylpropanimidate (**1a**).^{1a} Selected NOE difference data: *N*-Ph-*o*-H (6.75 ppm) experiences enhancements of 1.4 % for irradiation of $\text{CH}_2\text{-CH}_3$ (1.08 ppm), 2.6 % for irradiation of $\text{CH}_2\text{-CH}_3$ (2.17 ppm), and < 0.1 % for irradiation of OCH_2 (4.61 ppm), respectively. Irradiation of OCH_2 (4.61 ppm) causes no (< 0.2 %) enhancements for $\text{CH}_2\text{-CH}_3$ (2.17 ppm) or $\text{CH}_2\text{-CH}_3$ (1.08 ppm).

(*Z*)-2-Hexen-1-yl *N*-Phenylpropanimidate [(*Z*)-**1b**].^{1a} Selected NOE difference data: *N*-Ph-*o*-H (6.76 ppm) experiences enhancements of 1.3 % for irradiation of $\text{N}=\text{C-CH}_2\text{-CH}_3$ (1.06 ppm), 3.1 % for irradiation of $\text{N}=\text{C-CH}_2\text{-CH}_3$ (2.16 ppm), and < 0.1 % for irradiation of OCH_2 (4.72 ppm), respectively.

(*Z*)-2-Methyl-2-buten-1-yl *N*-Phenylpropanimidate [(*Z*)-**1c**]. $^1\text{H NMR } \delta$ 1.09 (t, 3 H, $J = 7.6$ Hz, $\text{CH}_2\text{-CH}_3$), 1.69 (br. d, 3 H, $J = 6.9$ Hz, $\text{C}=\text{CH-CH}_3$), 1.83 (br. s, 3 H, $\text{OCH}_2\text{-C-CH}_3$), 2.19 (q, 2 H, $J = 7.6$ Hz, $\text{CH}_2\text{-CH}_3$), 4.69 (s, 2 H, OCH_2), 5.49 (br. q, 1 H, $J = 6.9$ Hz, $\text{C}=\text{CH-CH}_3$), 6.75 - 7.32 (m, 5 H, H_{arom}); $^{13}\text{C NMR } \delta$ 11.0 (q), 13.3 (q), 21.5 (q), 23.3 (t), 64.1 (t), 121.1 (d), 122.6 (d), 123.8 (d), 128.8 (d), 131.6 (s), 148.9 (s), 164.4 (s); IR 1661 ($\text{C}=\text{N}$), 1596 ($\text{C}=\text{C}$) cm^{-1} ; MS m/e (relative intensity): 217 (M^+ , 15), 202 ($\text{M}^+ - \text{CH}_3$, 11), 188 ($\text{M}^+ - \text{C}_2\text{H}_5$, 4), 149 (21), 132 [$\text{M}^+ - \text{CH}_3\text{-CH}=\text{C}(\text{CH}_3)\text{-CH}_2\text{O}$, 23], 93 (Ph-NH_2^+ , 100), 77 (Ph^+ , 21), 69 [$\text{CH}_3\text{-CH}=\text{C}(\text{CH}_3)\text{-CH}_2^+$, 18]. Anal. Calcd for $\text{C}_{14}\text{H}_{19}\text{NO}$: C, 77.38; H, 8.81. Found: C, 77.18; H, 8.80.

(*Z*)-2-Trimethylsilyl-2-buten-1-yl *N*-Phenylpropanimidate (**1d**). $^1\text{H NMR } \delta$ 0.22 [s, 9 H, $\text{Si}(\text{CH}_3)_3$], 1.08 (t, 3 H, $J = 7.6$ Hz, $\text{CH}_2\text{-CH}_3$), 1.85 (d, 3 H, $J = 6.9$ Hz, $\text{C}=\text{CH-CH}_3$), 2.17 (q, 2 H, $J = 7.6$ Hz, $\text{CH}_2\text{-CH}_3$), 4.64 (s, 2 H, OCH_2), 6.42 (br. q, 1 H, $J = 6.9$ Hz, $\text{C}=\text{CH-CH}_3$), 6.70 - 7.33 (m, 5 H, H_{arom}); $^{13}\text{C NMR } \delta$ -0.3 (q), 11.0 (q), 17.5 (q), 23.3 (t), 72.3 (t), 121.1 (d), 122.5 (d), 128.8 (d), 136.0 (s), 141.5 (d), 149.0 (s), 164.0 (s); IR (film) 1666 ($\text{C}=\text{N}$), 1596 ($\text{C}=\text{C}$) cm^{-1} ; MS (GC/MS) m/e (relative intensity): 275 (M^+ , 4), 260 ($\text{M}^+ - \text{CH}_3$, 11), 246 ($\text{M}^+ - \text{C}_2\text{H}_5$, 2), 202 [$\text{M}^+ - (\text{CH}_3)_3\text{Si}$, 11], 132 [$\text{M}^+ - \text{CH}_3\text{-CH}=\text{C}(\text{Si}(\text{CH}_3)_3)\text{-CH}_2\text{O}$, 54], 93 (Ph-NH_2^+ , 33), 77 (Ph^+ , 17), 73 [$(\text{CH}_3)_3\text{Si}^+$, 100]. HRMS Calcd for $\text{C}_{16}\text{H}_{25}\text{NOSi}$ (M^+): 275.1705. Found: 275.1714.

(*E*)-2-Triethylsilyl-2-buten-1-yl *N*-Phenylpropanimidate (**1e**). $^1\text{H NMR } \delta$ 0.66 [q, 6 H, $J = 7.8$ Hz, $\text{Si}(\text{CH}_2\text{-CH}_3)_3$], 0.95 [t, 9 H, $J = 7.8$ Hz, $\text{Si}(\text{CH}_2\text{CH}_3)_3$], 1.08 (t, 3 H, $J = 7.6$ Hz, $\text{N}=\text{C-CH}_2\text{-CH}_3$), 1.82 (d, 3 H, $J = 6.6$ Hz, $\text{C}=\text{CH-CH}_3$), 2.18 (q, 2 H, $J = 7.6$ Hz, $\text{N}=\text{C-CH}_2\text{-CH}_3$), 4.81 (s, 2 H, OCH_2), 6.05 (br. q, 1 H, $J = 6.6$ Hz, $\text{C}=\text{CH-CH}_3$), 6.75 - 7.33 (m, 5 H, H_{arom}); $^{13}\text{C NMR } \delta$ 3.3 (t), 7.4 (q), 11.2 (q), 15.0 (q), 23.4 (t), 64.2 (t), 121.2 (d), 122.6 (d), 128.9 (d), 134.4 (s), 139.8 (d), 149.1 (s), 164.6 (s); IR 1660 ($\text{C}=\text{N}$), 1596 ($\text{C}=\text{C}$) cm^{-1} ; MS (GC/MS) m/e (relative intensity): 317 (M^+ , 3), 302 ($\text{M}^+ - \text{CH}_3$, 6), 288 ($\text{M}^+ - \text{C}_2\text{H}_5$, 46), 234 ($\text{M}^+ - \text{C}_2\text{H}_5 - \text{CH}_2=\text{C}=\text{CH-CH}_3$, 25), 202 [$\text{M}^+ - (\text{C}_2\text{H}_5)_3\text{Si}$, 29], 132 [$\text{M}^+ - \text{CH}_3\text{-CH}=\text{C}(\text{Si}(\text{C}_2\text{H}_5)_3)\text{-CH}_2\text{O}$, 100], 115 [$(\text{C}_2\text{H}_5)_3\text{Si}^+$, 32], 93 (Ph-NH_2^+ , 23), 87 (36), 77 (Ph^+ , 26), 59 (29). Anal. Calcd for $\text{C}_{19}\text{H}_{31}\text{NOSi}$: C, 71.85; H, 9.84. Found: C, 71.85; H, 9.88.

(*E*)-2-Buten-1-yl *N*-Phenylmethoxyacetimidate (**1i**). $^1\text{H NMR } \delta$ 1.76 (br. d, 3 H, $J = 6.0$ Hz, $\text{CH}=\text{CH}-\text{CH}_3$), 3.31 (s, 3 H, OCH_3), 3.93 (s, 2 H, CH_2-OCH_3), 4.68 (d, 2 H, $J = 6.1$ Hz, OCH_2), 5.77 (br. dt, 1 H, $J_d = 15.4$ Hz, $J_t = 6.1$ Hz, $\text{OCH}_2-\text{CH}=\text{CH}$), 5.87 (br. dq, 1 H, $J_d = 15.4$ Hz, $J_q = 6.0$ Hz, $\text{CH}=\text{CH}-\text{CH}_3$), 6.75 - 7.33 (m, 5 H, H_{arom}); $^{13}\text{C NMR } \delta$ 17.8 (q), 59.0 (q), 66.9 (t), 67.3 (t), 120.8 (d), 123.1 (d), 125.6 (d), 128.9 (d), 130.9 (d), 147.4 (s), 158.8 (s); IR 1670 (C=N), 1596 (C=C) cm^{-1} ; MS (GC/MS) m/e (relative intensity): 219 (M^+ , 16), 204 ($\text{M}^+ - \text{CH}_3$, 3), 174 ($\text{M}^+ - \text{CH}_3\text{O}-\text{CH}_2$, 30), 165 ($\text{M}^+ - \text{CH}_2=\text{C}=\text{CH}-\text{CH}_3$, 5), 135 (27), 120 ($\text{M}^+ - \text{CH}_3\text{O}-\text{CH}_2 - \text{CH}_2=\text{C}=\text{CH}-\text{CH}_3$, 21), 106 (33), 92 (25), 77 (Ph^+ , 20), 55 ($\text{CH}_3-\text{CH}=\text{CH}-\text{CH}_2^+$, 99), 45 ($\text{CH}_3\text{O}=\text{CH}_2^+$, 100). HRMS Calcd for $\text{C}_{13}\text{H}_{17}\text{NO}_2$ (M^+): 219.1259. Found: 219.1265.

Claisen Rearrangement to **3** via Deprotonation/Silylation of **1** - General Procedure

To a solution of diethylamine (3.2 mmol) in THF (7 ml) cooled to 0 °C is added dropwise *n*-BuLi (3 mmol) in hexane. The resultant solution of LDEA is cooled to -78 °C and allyl *N*-phenylimidate **1** (2 mmol) dissolved in THF (2 ml) is added. After stirring the mixture at -78 °C for 1 h, a solution of TBDMSCl (3.2 mmol) in hexamethylphosphoric triamide (1 ml)/THF (1 ml) is added and stirring is continued for 1 h at -20 °C.

Substrates **1** with $\text{R}^2 = \text{H}$ (Table 1): the mixture is stirred at room temperature for 24 h.

Substrates **1** with $\text{R}^2 \neq \text{H}$ (Table 1): the mixture is warmed to room temperature, decalin (10 ml) is added, and THF is removed by distillation under normal pressure using a Vigreux column. The reaction flask is equipped with a reflux condenser and after heating the mixture to 130 °C for 48 h, it is cooled to room temperature.

Work-up for all substrates **1**: the mixture is poured into sat. aqueous NH_4Cl (50 ml) and extracted with CH_2Cl_2 (3 x 20 ml). The combined extracts are washed successively with water (15 ml) and brine (15 ml), dried over MgSO_4 , and concentrated *in vacuo*. Flash chromatography (**3d**: ethyl acetate/petroleum ether 1:9; **3e**: CH_2Cl_2 ; **3i**: ethyl acetate/petroleum ether 1:6) affords the amides **3** as mixture of *syn/anti* diastereomers (for yields, see Table 1). Complete data of **3a-c** and **3f-h** as well as details for their chromatographic purification are listed in ref 1a. Attempted HPLC separation of *anti*- and *syn*-**3i** failed.

Diastereomeric ratios (Table 3) were determined by capillary GC analysis of the crude products using the following columns, temperatures, and heating rates - **3a**: column 3, 190 °C isothermal; **3b**: column 3, 210 °C isothermal; **3c,d,g**: column 1, 50 - 200 °C, 5 °C/min, then 200 °C isothermal; **3e**: column 2, 50 - 200 °C, 5 °C/min, then 200 °C isothermal; **3h**: column 3, 240 °C isothermal; **3i**: column 2, 150 °C isothermal.

anti-N-Phenyl-2,3-dimethyl-4-trimethylsilyl-4-pentenamide (*anti*-**3d**). m.p. 156 - 157 °C. $^1\text{H NMR } \delta$ 0.15 [s, 9 H, $\text{Si}(\text{CH}_3)_3$], 1.06 (d, 3 H, $J = 6.7$ Hz, $\text{CH}-\text{CH}_3$), 1.15 (d, 3 H, $J = 6.7$ Hz, $\text{CH}-\text{CH}_3$), 2.38 (dq, 1 H, $J_d = 9.5$ Hz, $J_q = 6.7$ Hz, $\text{CH}-\text{CH}_3$), 2.60 (dq, 1 H, $J_d = 9.5$ Hz, $J_q = 6.7$ Hz, $\text{CH}-\text{CH}_3$), 5.52 (br. s, 1 H, C=CH-H), 5.67 (br. s, 1 H, C=CH-H), 7.06 - 7.60 (m, 5 H, H_{arom}); $^{13}\text{C NMR } \delta$ -1.2 (q), 17.2 (q), 20.5 (q), 42.1 (d), 47.8 (d), 119.9 (d), 124.1 (d), 124.4 (t), 128.7 (d), 138.0 (s), 155.6 (s), 174.7 (s); IR 1688 (C=O), 1601 (C=C) cm^{-1} ; MS (GC/MS) m/e (relative intensity): 275 (M^+ , 3), 260 ($\text{M}^+ - \text{CH}_3$, 14), 202 [$\text{M}^+ - (\text{CH}_3)_3\text{Si}$, 6], 150 (4), 93 ($\text{Ph}-\text{NH}_2^+$, 28), 73 [$(\text{CH}_3)_3\text{Si}^+$, 100]. HRMS Calcd for $\text{C}_{16}\text{H}_{25}\text{NOSi}$ (M^+): 275.1705. Found: 275.1709.

syn-N-Phenyl-2,3-dimethyl-4-trimethylsilyl-4-pentenamide (*syn*-**3d**). MS (GC/MS) m/e (relative intensity): 275 (M^+ , 2), 260 ($\text{M}^+ - \text{CH}_3$, 15), 202 [$\text{M}^+ - (\text{CH}_3)_3\text{Si}$, 7], 150 (6), 93 ($\text{Ph}-\text{NH}_2^+$, 23), 73 [$(\text{CH}_3)_3\text{Si}^+$, 100].

anti-N-Phenyl-2,3-dimethyl-4-triethylsilyl-4-pentenamide (*anti*-**3e**). MS (GC/MS) m/e (relative intensity): 317 (M^+ , 2), 288 ($\text{M}^+ - \text{C}_2\text{H}_5$, 100), 202 [$\text{M}^+ - (\text{C}_2\text{H}_5)_3\text{Si}$, 5], 186 [$\text{M}^+ - (\text{C}_2\text{H}_5)_3\text{SiO}$, 6], 178 (9), 150 (6), 115 [$(\text{C}_2\text{H}_5)_3\text{Si}^+$, 11], 103 [$(\text{C}_2\text{H}_5)_2\text{Si}=\text{OH}^+$, 14], 93 ($\text{Ph}-\text{NH}_2^+$, 10), 87 (27), 75 (17), 59 (22).

syn-N-Phenyl-2,3-dimethyl-4-triethylsilyl-4-pentenamide (syn-3e). m.p. 79 - 81 °C. $^1\text{H NMR}$ δ 0.62 [q, 6 H, $J = 7.8$ Hz, Si(CH₂-CH₃)₃], 0.89 [t, 9 H, $J = 7.8$ Hz, Si(CH₂CH₃)₃], 1.02 (d, 3 H, $J = 7.1$ Hz, CH-CH₃), 1.20 (d, 3 H, $J = 6.8$ Hz, CH-CH₃), 2.46 (m_c, 1 H, CH-CH₃), 2.70 (m_c, 1 H, CH-CH₃), 5.45 (br. s, 1 H, C=CH-H), 5.80 (br. s, 1 H, C=CH-H), 7.00 - 7.51 (m, 5 H, H_{arom}); $^{13}\text{C NMR}$ δ 3.0 (t), 7.2 (q), 14.5 (q), 17.7 (q), 40.2 (d), 46.6 (d), 119.6 (d), 123.9 (d), 125.0 (t), 128.8 (d), 138.0 (s), 153.6 (s), 174.1 (s); IR 1676 (C=O), 1601 (C=C) cm⁻¹; MS (GC/MS) *m/e* (relative intensity): 317 (M⁺, 2), 288 (M⁺ - C₂H₅, 100), 202 [M⁺ - (C₂H₅)₃Si, 6], 186 [M⁺ - (C₂H₅)₃SiO, 10], 178 (11), 150 (10), 115 [(C₂H₅)₃Si⁺, 12], 103 [(C₂H₅)₂Si=OH⁺, 23], 93 (Ph-NH₂⁺, 15), 87 (42), 75 (38), 59 (53). Anal. Calcd for C₁₉H₃₁NOSi: C, 71.85; H, 9.84. Found: C, 71.91; H, 9.84.

anti-N-Phenyl-2-methoxy-3-methyl-4-pentenamide (anti-3i) and *syn-N-Phenyl-2-methoxy-3-methyl-4-pentenamide (syn-3i)*. $^1\text{H NMR}$ δ 1.07 (d, 3 H, $J = 7.0$ Hz, CH-CH₃, *syn-3i*), 1.18 (d, 3 H, $J = 7.0$ Hz, CH-CH₃, *anti-3i*), 2.67 - 2.86 (m, 1 H, CH-CH₃, *anti-3i* and *syn-3i*), 3.50 (s, 3 H, CH₃O, *syn-3i*), 3.52 (s, 3 H, CH₃O, *anti-3i*), 3.65 (d, 1 H, $J = 3.9$ Hz, CH-OCH₃, *anti-3i*), 3.72 (d, 1 H, $J = 3.7$ Hz, CH-OCH₃, *syn-3i*), 5.01 - 5.19 (m, 2 H, CH=CH₂, *anti-3i* and *syn-3i*), 5.82 (ddd, 1 H, $J = 7.8, 10.3, 17.3$ Hz, CH=CH₂, *anti-3i*), 5.92 (ddd, 1 H, $J = 7.2, 10.4, 17.4$ Hz, CH=CH₂, *syn-3i*), 7.05 - 7.65 (m, 5 H, H_{arom}, *anti-3i* and *syn-3i*); $^{13}\text{C NMR}$ δ 13.8 (q), 16.5 (q), 40.7 (d), 41.2 (d), 59.67 (q), 59.74 (q), 86.3 (d), 87.0 (d), 115.2 (t), 115.8 (t), 119.67 (d), 119.74 (d), 124.4 (d), 129.0 (d), 137.08 (s), 137.11 (s), 138.1 (d), 139.8 (d), 169.5 (s), 169.7 (s); IR 1675 (C=O), 1595 (C=C) cm⁻¹; MS (GC/MS, *anti-3i*) *m/e* (relative intensity): 219 (M⁺, 19), 204 (M⁺ - CH₃, 3), 189 (M⁺ - CH₂=O, 4), 188 (M⁺ - CH₃O, 4), 187 (M⁺ - CH₃OH, 14), 165 (M⁺ - CH₂=C=CH-CH₃, 7), 150 (M⁺ - CH₃ - CH₂=C=CH-CH₃, 5), 136 (21), 132 (14), 99 [CH₂=CH-CH(CH₃)-CH=OCH₃⁺, 100], 93 (Ph-NH₂⁺, 16), 77 (Ph⁺, 17), 67 [CH₂=CH-CH(CH₃)-CH=OCH₃⁺ - CH₃OH, 48]; MS (GC/MS, *syn-3i*) *m/e* (relative intensity): 219 (M⁺, 13), 204 (M⁺ - CH₃, 2), 189 (M⁺ - CH₂=O, 3), 188 (M⁺ - CH₃O, 5), 187 (M⁺ - CH₃OH, 21), 165 (M⁺ - CH₂=C=CH-CH₃, 6), 150 (M⁺ - CH₃ - CH₂=C=CH-CH₃, 5), 136 (21), 132 (12), 99 [CH₂=CH-CH(CH₃)-CH=OCH₃⁺, 100], 93 (Ph-NH₂⁺, 15), 77 (Ph⁺, 15), 67 [CH₂=CH-CH(CH₃)-CH=OCH₃⁺ - CH₃OH, 51]. HRMS Calcd for C₁₃H₁₇NO₂ (M⁺): 219.1259. Found: 219.1265.

Deprotonation / Alkylation of **1a**

Allyl *N*-phenylimidate **1a** (1 mmol) is deprotonated with LDEA as described above. Ethyliodide (3 mmol) is added at -78 °C, and stirring is continued for 2 h at -78 °C. The mixture is warmed to room temperature, poured into sat. aqueous NH₄Cl (40 ml), and extracted with ether (3 x). After washing with brine, drying over Na₂SO₄, and removal of the solvent *in vacuo*, pure **4** (83 %) is obtained as a colorless oil.

(*E*)-2-Buten-1-yl *N*-Phenyl-2-methylbutanimidate (**4**). $^1\text{H NMR}$ δ 0.81 (t, 3 H, $J = 7.4$ Hz, CH₂-CH₃), 1.08 (d, 3 H, $J = 6.9$ Hz, N=C-CH-CH₃), 1.19 - 1.40 (m, 1 H, CH₃-CH-H), 1.52 - 1.69 (m, 1 H, CH₃-CH-H), 1.75 (br. d, 3 H, $J = 6.1$ Hz, CH=CH-CH₃), 2.35 - 2.50 (m, 1 H, N=C-CH-CH₃), 4.60 (br. d, 2 H, $J = 5.8$ Hz, OCH₂), 5.70 (br. dt, 1 H, $J_d = 15.4$ Hz, $J_t = 5.8$ Hz, OCH₂-CH=CH), 5.81 (br. dq, 1 H, $J_d = 15.4$ Hz, $J_q = 6.1$ Hz, CH=CH-CH₃), 6.70 - 7.30 (m, 5 H, H_{arom}); $^{13}\text{C NMR}$ δ 12.0 (q), 17.8 (q), 18.3 (q), 27.1 (t), 36.0 (d), 65.9 (t), 121.1 (d), 122.4 (d), 126.3 (d), 128.8 (d), 129.4 (d), 148.9 (s), 165.5 (s); IR (film) 1655 (C=N), 1595 (C=C) cm⁻¹; MS (GC/MS) *m/e* (relative intensity): 231 (M⁺, 11), 216 (M⁺ - CH₃, 4), 203 (M⁺ - CH₂=CH₂, 3), 202 (M⁺ - C₂H₅, 2), 174 (M⁺ - C₂H₅-CH-CH₃, 6), 162 (M⁺ - CH₃ - CH₂=C=CH-CH₃, 15), 149 (M⁺ - CH₂=CH₂ - CH₂=C=CH-CH₃, 31), 147 (37), 93 (Ph-NH₂⁺, 57), 77 (Ph⁺, 29), 57 (C₂H₅-CH-CH₃⁺, 91), 55 (CH₃-CH=CH-CH₂⁺, 100). Anal. Calcd for C₁₅H₂₁NO: C, 77.89; H, 9.15. Found: C, 77.77; H, 9.35.

Isolation of *N*-Silyl Ketene *N,O*-Acetals - General Procedure

(*Z*)-2-Hexen-1-yl *N*-phenylpropanimidate (**[Z]-1b**) and ethyl *N*-phenylpropanimidate,²⁴ respectively, are deprotonated on a 2 mmol scale with LDEA at -78 °C and subsequently treated with *tert*-butyldimethylchlorosilane at -20 °C as described above. After stirring the resultant mixture at room temperature overnight, the solvent is removed *in vacuo* at room temperature. The residue is extracted inside the flask with pentane (3 x 20 ml), the combined pentane solutions are evaporated *in vacuo* at room temperature, and an

analytical sample of the remaining crude *N*-silyl ketene *N,O*-acetal is dissolved in CDCl₃. After passing a slow stream of argon through this solution for several minutes, it is analyzed by NMR spectroscopy. Aside from small amounts of the educt imidate and hexamethylphosphoric triamide, only a single *N*-silyl ketene *N,O*-acetal isomer is observed, respectively. (1*Z*,2'*Z*')-5b is obtained from (*Z*)-1b, and (*Z*)-14 is obtained from ethyl *N*-phenylpropanimidate.

(*Z*)-Methylketene-*O*-[(*Z*)-2-hexen-1-yl]-*N*-(*tert*-butyldimethylsilyl)-*N*-phenylacetal [(1*Z*,2'*Z*')-5b]. ¹H NMR δ 0.24 [s, 6 H, Si(CH₃)₂], 0.80 [s, 9 H, C(CH₃)₃], 1.20 - 1.35 (m, 2 H, CH₃-CH₂), 1.59 (d, 3 H, *J* = 6.7 Hz, C=CH-CH₃), 1.80 - 1.95 (m, 2 H, C₂H₅-CH₂), 4.15 (d, 2 H, *J* = 5.1 Hz, CH₂O), 4.40 (q, 1 H, *J* = 6.7 Hz, C=CH-CH₃), 5.33 - 5.46 (m, 2 H, CH=CH), 6.92 (tt, 1 H, *J* = 1.7, 6.8 Hz, *N*-Ph-*p*-H), 7.08 - 7.25 (m, 4 H, *N*-Ph-*o*-H, *N*-Ph-*m*-H); selected NOE difference data: irradiation of the 4 H multiplet for *N*-Ph-*o*-H and *N*-Ph-*m*-H (7.08 - 7.25 ppm) causes enhancements of 0.2 % for C=CH-CH₃ (1.59 ppm), 1.4 % for CH₂O (4.15 ppm), and 1.5 % for C=CH-CH₃ (4.40 ppm); ¹³C NMR δ -1.9 (q), 10.5 (q), 13.4 (q), 20.0 (s), 22.4 (t), 27.3 (q), 29.3 (t), 62.5 (t), 98.0 (d), 122.4 (d), 123.9 (d), 125.8 (d), 128.4 (d), 132.7 (d), 146.9 (s), 151.2 (s).

(*Z*)-Methylketene-*O*-ethyl-*N*-(*tert*-butyldimethylsilyl)-*N*-phenylacetal [(*Z*)-14]. ¹H NMR δ 0.22 [s, 6 H, Si(CH₃)₂], 0.80 [s, 9 H, C(CH₃)₃], 1.04 (t, 3 H, *J* = 7.0 Hz, CH₃-CH₂), 1.58 (d, 3 H, *J* = 6.7 Hz, C=CH-CH₃), 3.63 (q, 2 H, *J* = 7.0 Hz, CH₂O), 4.37 (q, 1 H, *J* = 6.7 Hz, C=CH-CH₃), 6.92 (tt, 1 H, *J* = 1.6, 6.9 Hz, *N*-Ph-*p*-H), 7.07 - 7.25 (m, 4 H, *N*-Ph-*o*-H, *N*-Ph-*m*-H); selected NOE difference data: irradiation of the 4 H multiplet for *N*-Ph-*o*-H and *N*-Ph-*m*-H (7.07 - 7.25 ppm) causes enhancements of 0.2 % for C=CH-CH₃ (1.58 ppm), 1.9 % for CH₂O (3.63 ppm), and 3.2 % for C=CH-CH₃ (4.37 ppm); ¹³C NMR δ -2.0 (q), 10.5 (q), 15.0 (q), 19.9 (s), 27.3 (q), 62.3 (t), 97.7 (d), 122.4 (d), 124.0 (d), 128.4 (d), 147.1 (s), 151.4 (s).

Desilylation

Of Anilide anti-3d. A mixture of *anti-3d* (71.0 mg, 0.258 mmol; *anti-3d*:*syn-3d* = 99.5:0.5 by capillary GC analysis), acetonitrile (2.6 ml), and 50 % aqueous HBF₄ (0.47 g, ca. 10 equiv.) is heated at 55 °C for 48 h. The mixture is cooled to room temperature, diluted with CH₂Cl₂ (50 ml), washed with sat. aqueous NaHCO₃ (10 ml) and brine (10 ml), and dried over MgSO₄. TLC (ethyl acetate/petroleum ether 1:6) indicated only a small amount of educt *anti-3d* aside from product *anti-3a*. After concentration *in vacuo*, a residue (52.2 mg) is obtained which consists solely of 85.5 % *anti-3a* (yield 85 %, 96 % on conversion) and 14.5 % educt *anti-3d* according to capillary GC analysis (column 3, 210 °C isothermal).

Of Anilide syn-3e. A mixture of *syn-3e* (102.0 mg, 0.321 mmol; *syn-3e*:*anti-3e* = 98.1:1.9 by capillary GC analysis - column 1, 50 - 200 °C, 5 °C/min, then 200 °C isothermal) and 65 % HF in pyridine (1.1 ml, 40.7 mmol HF) is stirred in a plastic vial for 1 h at room temperature. Another portion of HF solution is added (1.1 ml), and stirring is continued for 1 h at room temperature. The mixture is diluted with CH₂Cl₂ (10 ml), neutralized with 2 N NaOH at 0 °C and after addition of more CH₂Cl₂ (90 ml), it is washed with water (30 ml), brine (30 ml), and dried over MgSO₄. Removal of the solvent *in vacuo* and subsequent flash chromatography (ethyl acetate/petroleum ether 1:6) yields *syn-3a* (52.8 mg, 81 %; *syn-3a*:*anti-3a* = 98.0:2.0 by capillary GC analysis - column 4, 220 °C isothermal) as a colorless solid.

Acknowledgement

Financial support of this work by the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie is gratefully acknowledged.

REFERENCES AND NOTES

1. (a) Metz, P.; Mues, C. *Tetrahedron* **1988**, *44*, 6841-6853. (b) Metz, P.; Mues, C. *Synlett* **1990**, 97-98. (c) Metz, P.; Mues, C.; Schoop, A. *Tetrahedron* **1992**, *48*, 1071-1080.
2. For recent reviews on the Claisen rearrangement, see: (a) Pereira, S.; Srebnik, M. *Aldrichim. Acta* **1993**, *26*, 17-29. (b) Wipf, P. In *Comprehensive Organic Synthesis, Vol. 5, Combining C-C π -Bonds*; Paquette, L. A., Ed.; Pergamon Press: Oxford, 1991; pp 827-873. (c) Blechert, S. *Synthesis* **1989**, 71-82. (d) Ziegler, F. E. *Chem. Rev.* **1988**, *88*, 1423-1452.
3. For the Claisen rearrangement of *S*-allyl *N*-silyl ketene *N,S*-acetals, see: Tamaru, Y.; Furukawa, Y.; Mizutani, M.; Kitao, O.; Yoshida, Z. *J. Org. Chem.* **1983**, *48*, 3631-3639.
4. Metz, P. *Tetrahedron* **1993**, *49*, 6367-6374.
5. No or incomplete deprotonation of **1a** was observed with e.g. lithium di-*iso*-propylamide, lithium or potassium bis(trimethylsilyl)amide, and *n*-, *s*-, or *t*-butyllithium in the absence or presence of potassium *t*-butoxide.
6. Gluchowski, C.; Tiner-Harding, T.; Smith, J. K.; Bergbreiter, D. E.; Newcomb, M. *J. Org. Chem.* **1984**, *49*, 2650-2652.
7. For reviews on various aspects of imidate chemistry, see: *The Chemistry of Amidines and Imidates, Vol. 2*; Patai, S.; Rappoport, Z., Eds.; Wiley: New York, 1991.
8. A double methyl substitution at C-2 of imidates **1** precluded formation of the azaenolate, while a substrate **1** with R¹ = H was readily lithiated but underwent exclusive C-silylation.
9. (a) Eisch, J. J.; Damasevitz, G. A. *J. Org. Chem.* **1976**, *41*, 2214-2215. (b) Uchida, K.; Utimoto, K.; Nozaki, H. *J. Org. Chem.* **1976**, *41*, 2215-2217.
10. Corey, E. J.; Ritter, K.; Yus, M.; Nájera, C. *Tetrahedron Lett.* **1987**, *28*, 3547-3550.
11. Mikami, K.; Kishi, N.; Nakai, T. *Chem. Lett.* **1982**, 1643-1646.
12. Stork, G.; Jung, M. E.; Colvin, E.; Noel, Y. *J. Am. Chem. Soc.* **1974**, *96*, 3684-3686.
13. Zaidlewicz, M.; Uzarewicz, A.; Sarnowski, R. *Synthesis* **1979**, 62-64.
14. Lambling, M. E. *Bull. Soc. Chim. Fr.* **1897**, *17*, 356-362.
15. Nystrom, R. F.; Brown, W. G. *J. Am. Chem. Soc.* **1947**, *69*, 1197-1199.
16. For the sake of lucidity, this classification of imidates **1** as "(*E*)" or "(*Z*)" neglects the higher priority of silicon compared to carbon according to IUPAC rules for **1d** and **1e**.
17. Elucidation of the relative configuration of rearrangement products **3** is discussed in ref 1a. For preparation of the reference carboxylic acids converted to **3i**, see: Burke, S. D.; Fobare, W. F.; Pacofsky, G. J. *J. Org. Chem.* **1983**, *48*, 5221-5228. Stereochemical assignment for amides **3d** and **3e** follows from their desilylation to **3a**.
18. Ireland, R. E.; Mueller, R. H.; Willard, A. K. *J. Am. Chem. Soc.* **1976**, *98*, 2868-2877.
19. For a review, see: (a) Chan, T. H.; Fleming, I. *Synthesis* **1979**, 761-786. Aqueous HBF₄; (b) Ireland, R. E.; Varney, M. D. *J. Am. Chem. Soc.* **1984**, *106*, 3668-3670. HF in pyridine; (c) Overman, L. E.; Thompson, A. S. *J. Am. Chem. Soc.* **1988**, *110*, 2248-2256.
20. For the use of a trialkylsilyl group as temporary substituent for stereocontrol, see e.g.: (a) Hasan, I.; Kishi, Y. *Tetrahedron Lett.* **1980**, *21*, 4229-4232. (b) Boeckman Jr., R. K.; Barta, T. E. *J. Org. Chem.* **1985**, *50*, 3421-3423.
21. (a) Meese, C. O.; Walter, W.; Berger, M. *J. Am. Chem. Soc.* **1974**, *96*, 2259-2260. (b) Walter, W.; Meese, C. O. *Chem. Ber.* **1977**, *110*, 2463-2479. (c) Gallis, D. E.; Christ, D. R. *Magn. Reson. Chem.* **1987**, *25*, 480-483.
22. (a) Evans, D. A.; Nelson, J. V.; Taber, T. R. In *Topics in Stereochemistry, Vol. 13*; Allinger, N. L.; Eliel, E. L.; Wilen, S. H., Eds.; Wiley: New York, 1982; pp 1-115. For a review on A^{1,3}-strain, see: (b) Hoffmann, R. W. *Chem. Rev.* **1989**, *89*, 1841-1860.
23. Neuhaus, D.; Williamson, M. P. *The Nuclear Overhauser Effect in Structural and Conformational Analysis*; VCH: Weinheim, 1989.

24. DeWolfe, R. H. *J. Org. Chem.* **1962**, *27*, 490-493.
25. For imidate **1a**, changing the size of the silyl group on nitrogen from *tert*-butyldimethylsilyl to trimethylsilyl had no effect on the diastereoselectivity of the rearrangement, while the use of *tert*-butyldiphenylchlorosilane as silylating agent did not result in the formation of **3a**. Cf. a pronounced effect of such a variation for an Ireland Claisen rearrangement: Nagatsuma, M.; Shirai, F.; Sayo, N.; Nakai, T. *Chem. Lett.* **1984**, 1393-1396.
26. The reason for the reduced *anti* selectivity of imidate **1h** ($R^1 = \text{Ph}$) is not clear. Possibly, the acidifying phenyl substituent allows for a partial epimerization of anilide **3h** under the slightly basic reaction conditions.
27. A similar effect of substitution on the degree of simple diastereoselectivity has been noted for aza-Claisen rearrangements, but the interpretation given there is different: Kurth, M. J.; Decker, O. H. W. *J. Org. Chem.* **1986**, *51*, 1377-1383.

(Received in Germany 11 January 1994; accepted 2 February 1994)